Erika J Wolf1, Mark W Logue, Tawni B Stoop, Steven A Schichman, Annjanette Stone, Naomi Sadeh, Jasmeet P Hayes, Mark W Miller. 1. From the National Center for PTSD (Wolf, Logue, Sadeh, Hayes, Miller), Behavioral Science Division, VA Boston Healthcare System; Department of Psychiatry (Wolf, Sadeh, Hayes, Miller), Boston University School of Medicine; Biomedical Genetics (Logue), Boston University School of Medicine; Department of Biostatistics (Logue), Boston University School of Public Health; Research Service (Stoop), VA Boston Healthcare System; and Pharmacogenomics Analysis Laboratory (Schichman, Stone), Research Service, Central Arkansas Veterans Healthcare System, Boston, Massachusetts.
Abstract
OBJECTIVE: Recently developed indices of cellular age based on DNA methylation (DNAm) data, referred to as DNAm age, are being used to study factors that influence the rate of aging and the health correlates of these metrics of the epigenetic clock. This study evaluated associations between trauma exposure, posttraumatic stress disorder (PTSD) symptoms, and accelerated versus decelerated DNAm age among military veterans. We also examined whether accelerated DNAm age predicted mortality over the course of a 6.5-year medical record review period. METHODS: Three hundred thirty-nine genotype-confirmed white, non-Hispanic, middle-aged, trauma-exposed veterans underwent psychiatric assessment and genome-wide DNAm analysis. DNAm age was calculated using a previously validated algorithm. Medical records were available for a subset of 241 veterans and were reviewed approximately 6.5 years after DNA collection and PTSD assessment. RESULTS: PTSD hyperarousal symptoms were associated with accelerated DNAm age (β = 0.20, p = .009) but trauma exposure and total PTSD severity were not. Accelerated DNAm age was also associated with 13% increased risk for all-cause mortality (hazard ratio = 1.13, 95% confidence interval = 1.01-1.26) during the medical record review period. CONCLUSIONS: Findings of this study replicate the association between PTSD and accelerated DNAm age and suggest that this effect may be specific to the hyperarousal symptom cluster. Results point to the potential utility of DNAm age algorithms for identifying individuals who are aging at an accelerated rate and for determining the factors that influence this process.
OBJECTIVE: Recently developed indices of cellular age based on DNA methylation (DNAm) data, referred to as DNAm age, are being used to study factors that influence the rate of aging and the health correlates of these metrics of the epigenetic clock. This study evaluated associations between trauma exposure, posttraumatic stress disorder (PTSD) symptoms, and accelerated versus decelerated DNAm age among military veterans. We also examined whether accelerated DNAm age predicted mortality over the course of a 6.5-year medical record review period. METHODS: Three hundred thirty-nine genotype-confirmed white, non-Hispanic, middle-aged, trauma-exposed veterans underwent psychiatric assessment and genome-wide DNAm analysis. DNAm age was calculated using a previously validated algorithm. Medical records were available for a subset of 241 veterans and were reviewed approximately 6.5 years after DNA collection and PTSD assessment. RESULTS:PTSD hyperarousal symptoms were associated with accelerated DNAm age (β = 0.20, p = .009) but trauma exposure and total PTSD severity were not. Accelerated DNAm age was also associated with 13% increased risk for all-cause mortality (hazard ratio = 1.13, 95% confidence interval = 1.01-1.26) during the medical record review period. CONCLUSIONS: Findings of this study replicate the association between PTSD and accelerated DNAm age and suggest that this effect may be specific to the hyperarousal symptom cluster. Results point to the potential utility of DNAm age algorithms for identifying individuals who are aging at an accelerated rate and for determining the factors that influence this process.
Authors: O Troyanskaya; M Cantor; G Sherlock; P Brown; T Hastie; R Tibshirani; D Botstein; R B Altman Journal: Bioinformatics Date: 2001-06 Impact factor: 6.937
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Sabrina M Darrow; Josine E Verhoeven; Dóra Révész; Daniel Lindqvist; Brenda W J H Penninx; Kevin L Delucchi; Owen M Wolkowitz; Carol A Mathews Journal: Psychosom Med Date: 2016-09 Impact factor: 4.312
Authors: Marco P Boks; Hans C van Mierlo; Bart P F Rutten; Timothy R D J Radstake; Lot De Witte; Elbert Geuze; Steve Horvath; Leonard C Schalkwyk; Christiaan H Vinkers; Jasper C A Broen; Eric Vermetten Journal: Psychoneuroendocrinology Date: 2014-07-23 Impact factor: 4.905
Authors: Riccardo E Marioni; Sonia Shah; Allan F McRae; Stuart J Ritchie; Graciela Muniz-Terrera; Sarah E Harris; Jude Gibson; Paul Redmond; Simon R Cox; Alison Pattie; Janie Corley; Adele Taylor; Lee Murphy; John M Starr; Steve Horvath; Peter M Visscher; Naomi R Wray; Ian J Deary Journal: Int J Epidemiol Date: 2015-01-22 Impact factor: 7.196
Authors: Andrew E Teschendorff; Francesco Marabita; Matthias Lechner; Thomas Bartlett; Jesper Tegner; David Gomez-Cabrero; Stephan Beck Journal: Bioinformatics Date: 2012-11-21 Impact factor: 6.937
Authors: Erika J Wolf; Mark W Logue; Xiang Zhao; Nikolaos P Daskalakis; Filomene G Morrison; Shaline Escarfulleri; Annjanette Stone; Steven A Schichman; Regina E McGlinchey; William P Milberg; Cidi Chen; Carmela R Abraham; Mark W Miller Journal: Psychoneuroendocrinology Date: 2020-04-13 Impact factor: 4.905
Authors: Erika J Wolf; Filomene G Morrison; Danielle R Sullivan; Mark W Logue; Rachel E Guetta; Annjanette Stone; Steven A Schichman; Regina E McGlinchey; William P Milberg; Mark W Miller Journal: Brain Behav Immun Date: 2019-03-11 Impact factor: 7.217
Authors: Erika J Wolf; Hannah Maniates; Nicole Nugent; Adam X Maihofer; Don Armstrong; Andrew Ratanatharathorn; Allison E Ashley-Koch; Melanie Garrett; Nathan A Kimbrel; Adriana Lori; Allison E Aiello; Dewleen G Baker; Jean C Beckham; Marco P Boks; Sandro Galea; Elbert Geuze; Michael A Hauser; Ronald C Kessler; Karestan C Koenen; Mark W Miller; Kerry J Ressler; Victoria Risbrough; Bart P F Rutten; Murray B Stein; Robert J Ursano; Eric Vermetten; Christiaan H Vinkers; Monica Uddin; Alicia K Smith; Caroline M Nievergelt; Mark W Logue Journal: Psychoneuroendocrinology Date: 2017-12-27 Impact factor: 4.905
Authors: Erika J Wolf; Mark W Logue; Filomene G Morrison; Elizabeth S Wilcox; Annjanette Stone; Steven A Schichman; Regina E McGlinchey; William P Milberg; Mark W Miller Journal: Psychol Med Date: 2018-06-13 Impact factor: 7.723
Authors: Samantha L Connolly; Tawni B Stoop; Mark W Logue; Esther Hana Orr; Immaculata De Vivo; Mark W Miller; Erika J Wolf Journal: J Trauma Stress Date: 2018-10-19
Authors: Erika J Wolf; Ci-Di Chen; Xiang Zhao; Zhenwei Zhou; Filomene G Morrison; Nikolaos P Daskalakis; Annjanette Stone; Steven Schichman; Jaclyn Garza Grenier; Dana Fein-Schaffer; Bertrand R Huber; Carmela R Abraham; Mark W Miller; Mark W Logue Journal: Neuropsychopharmacology Date: 2020-10-23 Impact factor: 7.853